Skip to main content

Table 3 The 558 rheumatoid arthritis patients’ baseline clinical and laboratory data and treatment information

From: Utility of the GerdQ questionnaire in detecting gastroesophageal symptoms with RA patients

 

Before propensity matching

 

After propensity matching

All patients

n = 558

Low GerdQ score

n = 482

High GerdQ score

n = 76

 

Low GerdQ score

n = 67

High GerdQ score

n = 68

Age

65.4 ± 0.6

68.0 ± 1.6

 

65.5 ± 1.7

68.0 ± 1.7

Female (%)

72.6

80.0

 

82.4

82.4

Disease duration, months

63.5 [38.3–152.0]

84.0 [37.0–162.5]

 

81.0 [40.0–164.0]

84.0 [37.0–165.8]

RF (%), titers

55.1, 20.0 [5.0-66.3]

59.5, 24.0 [6.0-77.3]

 

57.4, 20.0 [6.0-67.8]

61.8, 24.0 [6.0-77.5]

ACPA (%), titers

58.6, 17.3 [0.0-124.8]

54.7, 16.2 [0.0-131.1]

 

58.8, 18.9 [0.0-183.3]

55.9, 16.1 [0.0-126.8]

Medication

     

PPI or P-CAB (%)

43.7

48.0

 

46.0

49.2

Histamine H2 receptor antagonist (%)

4.8

6.7

 

3.2

6.4

Gastric mucosa protectant (%)

16.8

13.3

 

19.1

12.7

NSAIDs (%)

20.5

21.3

 

23.8

17.5

COX-II inhibitor/Others (%)

7.5/13.0

6.7/13.6

 

12.7/11.1

4.8/12.7

csDMARDs (%)

     

SASP/IGU/BUC/TAC (%)

30.6/38.0/2.9/6.2

33.3/40.0/2.7/2.8

 

34.9/33.3/4.8/9.8

34.9/40.0/3.2/3.3

bDMARDs (%)

57.0

60.7

 

58.6

60.6

Previously failed > 1 bDMARDs (%)

14.7

20.0

 

12.9

23.1*

TNFi/IL-6Ri/CTLA4-Ig (%)

12.5/32.5/12.0

14.7/32.0/14.0

 

8.8/35.2/14.6

14.7/30.3/15.6

tsDMARDs (%)

12.1

10.9

 

7.0

15.1

Body Mass Index

22.3 ± 3.8

23.0 ± 3.5

 

22.8 ± 3.9

22.9 ± 3.6

Comorbidities (%)

     

Hypertension, (%)

26.6

21.3

 

28.6

24.6

Dyslipidemia (%)

26.2

21.3

 

31.4

21.5

Diabetes (%)

12.6

10.7

 

15.7

9.2

Cerebrocardiovascular diseases (%)

5.2

5.3

 

7.1

6.2

Any Lung diseases (%)

1.4

1.2

 

1.1

1.3

Smoking: Current/Past (%)

10.8/31.9

9.3/33.3

 

9.7/24.3

10.8/33.9

Alchol: Current/Past (%)

21.1/23.2

14.7/27.0

 

13.5/25.0

11.7/28.4

Steinbrocker Stage/Class

1.8 ± 0.1/1.4 ± 0.7

1.7 ± 0.2/1.4 ± 0.2

 

1.8 ± 1.1/1.4 ± 0.9

1.6 ± 1.2/1.3 ± 1.1

HAQDI, range 0–3

0.1 [0.0–0.6]

0.4 [0.0–1.0] **

 

0.2 [0.0–0.3]

0.3 [0.2–0.5]

  1. PPI: proton pump inhibitor, P-CAB: potassium-competitive acid blocke, NSAIDs: non-steroidal anti-inflammatory drugs, COX: cyclooxygenase, csDMARDs: conventional synthetic disease-modifying antirheumatic drugs, SASP: Salazosulfapyridine, IGU: Iguratimod, BUC: Bucillamine, TAC: Tacrolimus, bDMARDs: biological disease-modifying antirheumatic drugs, TNFi: tumor necrosis factor inhibitor, IL-6Ri: interleukin-6 receptor inhibitor, CTLA-Ig: cytotoxic T-lymphocyte-associated protein 4-immunoglobulin, tsDMARDs: targeted synthetic disease-modifying antirheumatic drugs, GCs: glucocorticoids, HAQDI: health assessment questionnaire disability index. We calculated the propensity scores from a logistic regression model with the following variables: age, gender, body mass index (BMI), duration of RA, history of smoking and drinking alcohol, current medication of NSAIDs, GCs, PPI or P-CAB, the positivity of RF and ACPA, and then, we matched these scores one by one using nearest-neighbor methods without replacement, and no caliper width. Through the matching procedure for propensity scores, the two groups showed similar distributions of propensity scores, indicating that the differences in covariates between the two groups were minimized. Summary statistics of the mean ± standard deviation (SD) or the median and interquartile range (IQR) are presented for continuous variables as appropriate. Categorical variables are presented as percentages. Comparisons between independent means were analyzed using the Mann-Whitney test and paired t-test (*p < 0.05, **p < 0.01). A GerdQ score of 8 or above was defined as the high GerdQ score group, while a score below 8 was defined as the low GerdQ score group
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us